Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Jan 20, 2023 10:27am
132 Views
Post# 35235409

RE:RE:RE:RE:RE:RE:2-million-dollar fee

RE:RE:RE:RE:RE:RE:2-million-dollar fee""Put a logical finance plan together for a 0 or Plb trial on xB3 into action in Canada"

how much time/years for this to happen?? How much time & money to get the new bod ,ceo etc etc in place before the aboce even happens?"

The logical plan to do what is right for the business is to wipe out the debt, create a path to a two year cash runway to key catalysts, pick up scale as with Midatech to support stronger deals, pick up a complementary asset for xB3 such as Midatech's glioblastoma drug which significantly expresses the same receptor xB3 uses, pick up a complementary technology to xB3 such as Midatech's Q-Sphera which can create extended release drugs helping to potentially further differentiate xB3 drugs from the competition, and pick up clinical trial assets such as Midatech's which could create a cash runway to support a pipeline of development stage assets in the future thereby limiting dilution.  

  

"It's also essential to recognize one of the main receptors Transcend utilizes to trick the brain into opening the BBB is expressed in important regions of the brain, including areas critical to learning, memory, mood and impulsivity. This receptor is significantly expressed in glioblastomas and in key areas of the brain involved in a plethora of psychiatric and neurological diseases. I think these represent very intriguing targets for biOasis." 2017 news release

Doing what's right for the business can ultimately pay off in the end.
<< Previous
Bullboard Posts
Next >>